CapyFin

Calendar Reports Pricing

Search for a symbol...

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2026 CapyFin. All rights reserved.

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

GeneDx Holdings Corp (WGS) Financial Analysis | CapyFin

GeneDx Holdings Corp

WGS · NASDAQ🇺🇸

Earnings Dividends Seasonality Metrics

Reported earnings 10 days ago

Exome & Genome Revenue Growth

Exome & Genome Volume Growth

Adjusted Gross Margin

Cash and Equivalents

Loading...

Key Statistics

Market Cap

$2.25B

P/E Ratio

494.00

Sector

N/A

Industry

N/A

52-Week High

$167

52-Week Low

$74.1

Exome & Genome Revenue Growth

32%

Exome & Genome Volume Growth

34.3%

Adjusted Gross Margin

71.1%

Adjusted Net Income

$4.4M

Exome & Genome Test Results

27.76K

GeneDx Holdings Corp

GeneDx Holdings Corp

GeneDx Holdings Corp Revenue by Segment

Revenue by Segment

Diagnostic Test Revenue

CapyFin.com

Other Revenue

CapyFin.com

Whole Exome & Genome Revenue

CapyFin.com

Hereditary Cancer Revenue

CapyFin.com

Other Panels Revenue

CapyFin.com

Data Information Revenue

CapyFin.com

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...